Packaging and tiers vs the traditional approach: what actually beats what for healthcare and life sciences in emerging markets

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in emerging markets. In this market, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint, so the way you install packaging and tiers has to be shaped to that reality from day one.

The debate about packaging and tiers is often framed as replacement — new model wipes out old. That framing is wrong. The right question is where each approach wins.

Packaging and tiers wins on speed of learning, targeting precision, and cost per outcome. It is the shape of the offer that channels buyers into the right plan, and it compounds in ways the traditional approach cannot match.

The traditional approach wins on relationship depth, brand consistency, and situations where the buyer has already self-identified. Ignoring that is why some teams' first packaging and tiers attempt underperforms — they replace the wrong parts.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in emerging markets it is compounded by the fact that operating footprint and pricing fit, not brand awareness is what actually gates growth. Packaging and tiers is only useful here when it is pointed at both constraints at once.

Combine them deliberately. Use packaging and tiers to find and qualify; use the traditional approach to close and expand. The seam between them is where most pipeline is lost or won.

Metric to watch when running both: average contract value by tier, plus source attribution. The two approaches should not cannibalise each other; if they do, your handoff is broken.

The failure mode of running both is three tiers labelled small, medium, large that mean nothing — usually because the traditional team feels threatened and the new model is starved of context.

Companies that get this right end up with a hybrid engine that outperforms either pure model. Companies that pick one and evangelise it lose to the ones that combine.

Concretely for healthcare and life sciences in emerging markets: the healthcare teams that install this get past procurement instead of dying in it, and the teams that install this early own the category before Western vendors even show up. That is the reason it is worth installing packaging and tiers deliberately for this market rather than importing a playbook designed for somewhere else.